The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
Author:
Funder
Merck
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12325-021-01913-5.pdf
Reference33 articles.
1. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.
2. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016;95(35): e4614.
3. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African–American women: implications for breast cancer screening recommendations. Cancer. 2011;117(12):2747–53.
4. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–82.
5. Dehghani M, Keshavarz P, Talei A, Akrami M, Tahmasebi S, Safaie A, et al. The effects of low HER2/neu expression on the clinicopathological characteristics of triple-negative breast cancer patients. Asian Pac J Cancer Prev. 2020;21(10):3027–32.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework;Journal of Medical Economics;2024-07
2. Prostate Specific Membrane Antigen Expression in a Syngeneic Breast Cancer Mouse Model;Molecular Imaging and Biology;2024-05-17
3. Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data;Journal of Medical Economics;2023-12-19
4. A systematic literature review on direct and indirect costs of triple-negative breast cancer;Cost Effectiveness and Resource Allocation;2023-11-30
5. Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis;Supportive Care in Cancer;2023-11-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3